Bulletin
Investor Alert

Novo Nordisk A/S ADR

NYS: NVO

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 18, 2020, 4:41 p.m.

NVO
/zigman2/quotes/203484366/composite

$

69.44

Change

0.00 0.00%

Volume

Volume 1,992

Quotes are delayed by 20 min

/zigman2/quotes/203484366/composite

Previous close

$ 69.57

$ 69.44

Change

-0.13 -0.19%

Day low

Day high

$68.76

$69.50

Open

52 week low

52 week high

$49.24

$69.75

Open

Company Description

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; G...

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Valuation

P/E Current

26.57

P/E Ratio (with extraordinary items)

24.63

P/E Ratio (without extraordinary items)

23.57

Price to Sales Ratio

7.54

Price to Book Ratio

15.79

Price to Cash Flow Ratio

19.65

Enterprise Value to EBITDA

15.74

Enterprise Value to Sales

7.45

Total Debt to Enterprise Value

0.00

Efficiency

Revenue/Employee

2,820,773.00

Income Per Employee

900,435.00

Receivables Turnover

4.93

Total Asset Turnover

1.03

Liquidity

Current Ratio

1.06

Quick Ratio

0.76

Cash Ratio

0.26

Profitability

Gross Margin

82.63

Operating Margin

43.48

Pretax Margin

39.90

Net Margin

31.92

Return on Assets

32.96

Return on Equity

71.19

Return on Total Capital

92.74

Return on Invested Capital

69.28

Capital Structure

Total Debt to Total Equity

7.78

Total Debt to Total Capital

7.22

Total Debt to Total Assets

3.57

Long-Term Debt to Equity

5.22

Long-Term Debt to Total Capital

4.85

Officers and Executives

Name Age Officer Since Title
Mr. Lars Fruergaard Jørgensen 53 1991 SVP-Information Technology & Corporate Development
Mr. Maziar Mike Doustdar 49 1992 VP-Business Area Oceania & South East Asia
Mr. Karsten Munk Knudsen 47 - Senior Vice President-Finance
Dr. Mads Krogsgaard Thomsen 59 1991 Director, Chief Science Officer & EVP
Dr. Stephen Gough - 2015 Global Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/nvo

MarketWatch News on NVO

  1. Novo Nordisk tops estimates as costs fall

    2:36 a.m. Aug. 6, 2020

    - MarketWatch.com

  2. A Pioneer ESG Fund Is Still Shooting Out the Lights

    9:30 p.m. July 17, 2020

    - Barron's Online

  3. 12 European Stocks for the Second Half of 2020

    12:46 p.m. June 30, 2020

    - Barron's Online

  4. Stockpiling helps Novo Nordisk beat forecasts

    2:19 a.m. May 6, 2020

    - MarketWatch.com

  5. How to Invest in a Time of Turmoil

    6:05 p.m. March 20, 2020

    - Barron's Online

  6. Novo Nordisk posts fourth-quarter revenue beat

    4:24 a.m. Feb. 5, 2020

    - MarketWatch.com

  7. Sanofi Stock Is Undervalued, J.P. Morgan Says

    11:22 a.m. Jan. 6, 2020

    - Barron's Online

  8. Insulin-giant Sanofi to exit diabetes research

    10:38 p.m. Dec. 9, 2019

    - MarketWatch.com

  9. Arrowhead Stock’s Surge Will Continue, Analyst Says

    10:53 a.m. Nov. 29, 2019

    - Barron's Online

  10. Novo Nordisk downgraded by UBS on concerns over drug launch cost

    6:19 a.m. Nov. 18, 2019

    - Steve Goldstein

  11. Financing Global Health

    12:28 p.m. Sept. 25, 2019

    - Barron's Online

  12. Novo Nordisk climbs after lifting outlook

    5:53 a.m. Aug. 9, 2019

    - MarketWatch.com

  13. 3 stocks that can make you money despite a trade war or recession

    7:31 a.m. July 21, 2019

    - Philip van Doorn

  14. Loading more headlines...
/news/nonmarketwatch/company/us/nvo

Other News on NVO

  1. Type 2 diabetes landscape during COVID-19

    7:01 a.m. Sept. 10, 2020

    - CNW Group

  2. The Top 7 Healthcare Stocks You Should Be Watching

    10:36 a.m. Sept. 9, 2020

    - InvestorPlace.com

  3. Nicholas Ward's Dividend Growth Portfolio: August 2020 Review

    6:59 a.m. Sept. 7, 2020

    - Seeking Alpha

  4. 7 Cheap Stocks for the Cash-Strapped Investor

    1:21 p.m. Sept. 2, 2020

    - InvestorPlace.com

  5. Novo teams up with Evotec in kidney diseases

    6:08 a.m. Aug. 18, 2020

    - Seeking Alpha

  6. Novo Nordisk: Long-Term Growth By CV Risk Factor Reduction

    8:26 a.m. Aug. 17, 2020

    - Seeking Alpha

  7. Novo Nordisk: A Solid And Expanding Pharmaceutical Titan

    4:43 a.m. Aug. 17, 2020

    - Seeking Alpha

  8. Nicholas Ward's Dividend Growth Portfolio: July 2020 Update

    10:21 a.m. Aug. 10, 2020

    - Seeking Alpha

  9. Biotech's Q2:  Lots Of Candidates That May Deliver Alpha

    12:29 p.m. Aug. 9, 2020

    - Seeking Alpha

  10. Emeth Value Capital H1 2020 Letter

    2:05 a.m. Aug. 7, 2020

    - Seeking Alpha

  11. Novo Nordisk A/S 2020 Q2 - Results - Earnings Call Presentation

    11:10 a.m. Aug. 6, 2020

    - Seeking Alpha

  12. 10-Q: DICERNA PHARMACEUTICALS INC

    7:13 a.m. Aug. 6, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  13. Nasdaq Indexes Lead Way on Both Sides of Atlantic

    5:30 a.m. Aug. 3, 2020

    - Ben Dummett

  14. Trump’s Drug Price Panic

    5:19 p.m. July 26, 2020

    - The Editorial Board

  15. Apple Pledges to Be Carbon Neutral by 2030

    7:09 p.m. July 21, 2020

    - Sarah E. Needleman

  16. Loading more headlines...

At a Glance

Novo Nordisk A/S

Novo Allé

Bagsværd, CR 2880

Phone

45 44448888

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$122.02B

Net Income

$38.95B

2019 Sales Growth

9.1%

Employees

43,258

/news/pressrelease/company/us/nvo

Press Releases on NVO

  1. Loading more headlines...
Link to MarketWatch's Slice.